Clinicians have injected Intradose by using CT and ultrasound scans to target it directly into tumors, the meeting of the Radiological Society of North America in Chicago, USA, was told.
The conference heard that a trial had been conducted on 38 cases of inoperable primary liver cancer at the John Hopkins University Medical Center, Baltimore, Maryland.
Another 13 patients have taken part in a Phase-II ultrasound trial at the Prince of Wales Hospital, Hong Kong, China.
And at the Johann Wolfgang Goethe University, Frankfurt, Germany, CT scans have been used to test the treatment on 9 primary and 8 secondary liver cancer patients.
Intradose, developed by Matrix Pharmaceutical, of Fremont, California, USA, contains the anti-cancer agent cisplatin. The treatment has orphan drug status for head and neck cancer treatment in the USA.
The Baltimore study used both ultrasound and CT scans. Complete tumor destruction was seen in 9 patients - 24 per cent - while in 21 cases, or 55 per cent, tumors shrank by at least half, according to Dr Jeff Geschwind, director of interventional radiology research at the center.
After Intradose treatment:
- 24% of tumors were completely destroyed
- 55% shrank by at least half
Dr Geschwind said, "For the first time we can effectively inject a chemotherapy agent directly into these tumors. Using ultrasound to precisely and accurately place the injections, we can see a zone of spreading brightness in real time that shows Intradose penetrating the tumor.
"Although we are still collecting data, what we have seen so far is encouraging. The treatment is generally well tolerated and may improve patients' quality of life."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com